NEW YORK (GenomeWeb News) – Danish diagnostics firm Dako today said that it has signed an agreement to provide companion diagnostics for Genentech's trastuzumab (Herceptin) for patients with advanced HER2-positive stomach cancer.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.
At Nature, John Wilbanks and Eric Topol call for openness in health data.
Law.com predicts that genomic and genetic testing will become common in toxic tort cases.
A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.